Marfan syndrome is an inherited connective tissue disorder caused by pathogenic variants in the FBN1 gene. It is inherited in an autosomal dominant pattern and primarily affects the cardiovascular, ocular, and skeletal systems. The alteration of fibrillin-1 compromises the structure of microfibrils and the regulation of the extracellular matrix, which favors manifestations such as aortic root dilation, ectopia lentis, and bone abnormalities.
Marfan syndrome (FBN1 gene)
The FBN1 gene encodes fibrillin-1, a glycoprotein essential for the formation of extracellular microfibrils. These structures provide elasticity and strength to connective tissue and participate in the organization of elastic fibers in blood vessels, ligaments, skin, lungs, and other tissues. Furthermore, fibrillin-1 contributes to regulating the availability of growth factors, especially from the TGF-β pathway, which is involved in tissue growth and repair. When FBN1 presents pathogenic variants, fibrillin-1 can be abnormal or produced in insufficient quantities. As a consequence, connective tissue loses stability and arterial walls, especially the aorta, become more susceptible to dilation, aneurysm, and dissection. The disease is inherited in an autosomal dominant manner; approximately three-quarters of cases are familial, and the rest correspond to de novo variants. The estimated prevalence is around 1 in 5,000-10,000 people, with no clear ethnic predilection. Clinical expressivity is variable even among members of the same family.
Symptoms
Marfan syndrome can manifest from infancy to adulthood. The most frequent features include tall stature, long and thin limbs, arachnodactyly, scoliosis, joint hypermobility, pectus excavatum or carinatum, and ectopia lentis. The most relevant complication due to its severity is the progressive dilation of the aortic root, which can evolve to aneurysm or dissection. The clinical diagnosis is supported by the revised Ghent criteria, along with cardiovascular, ophthalmological, skeletal, and genetic evaluation.
Disease management
Management aims to prevent cardiovascular complications and requires multidisciplinary follow-up. Regular monitoring of the aorta through echocardiography or other imaging techniques, strict blood pressure control, and the use of beta-blockers or angiotensin II receptor blockers, such as losartan, when indicated, are essential. If the aortic root reaches risk thresholds or grows rapidly, prophylactic surgery may be recommended. It is also advisable to avoid contact sports or intense isometric exertion and to undergo ophthalmological and traumatological follow-up according to individual manifestations.
Genes analyzed
Bibliography
Du Q, Zhang D, Zhuang Y, et al. The Molecular Genetics of Marfan Syndrome. Int J Med Sci. 2021 May 27;18(13):2752-2766.
Coelho SG, Almeida AG. Marfan syndrome revisited: From genetics to the clinic. Rev Port Cardiol (Engl Ed). 2020 Apr;39(4):215-226.
Zeigler SM, Sloan B, Jones JA. Pathophysiology and Pathogenesis of Marfan Syndrome. Adv Exp Med Biol. 2021;1348:185-206.
Spencer M. Marfan syndrome. Nursing. 2024 Apr 1;54(4):19-25.
